Do CDK4/6 inhibitors have potential as targeted therapeutics for squamous cell cancers?

Published on Jan 1, 2017in Expert Opinion on Investigational Drugs5.081
· DOI :10.1080/13543784.2017.1274731
Nene N. Kalu8
Estimated H-index: 8
(University of Texas MD Anderson Cancer Center),
Faye M. Johnson37
Estimated H-index: 37
Sources
Abstract
ABSTRACTIntroduction Dysregulation of cell cycle progression has an established link to neoplasia and cancer progression. Components of the cyclin D-CDK4/6-INK4-Rb pathway are frequently altered in squamous cell carcinomas (SCCs) by diverse mechanisms, including viral oncogene–induced degradation, mutation, deletion, and amplification. Activation of the CDK4/6 pathway may predict response to CDK4/6 inhibitors and provide clinical biomarkers. Recently, the CDK4/6 inhibitor palbociclib showed clinical efficacy in combination with cetuximab in HNSCC patients.Areas covered This review focuses on the current research on the use of CDK4/6 inhibitors, comprising preclinical animal studies through phase II clinical trials across all SCCs.Expert opinionCDK4/6 inhibitors have a proven clinical benefit in breast cancer, but data on SCCs are sparse. Although frequent dysregulation of the cyclin D-CDK4/6-INK4-Rb pathway in SCCs suggests that targeting CDK4/6 may hold promise for improved clinical outcomes, single-agen...
📖 Papers frequently viewed together
4 Citations
20 Citations
1 Citations
References98
Newest
#1Maura L. Gillison (OSU: Ohio State University)H-Index: 81
#2George R. Blumenschein (University of Texas MD Anderson Cancer Center)H-Index: 68
Last. Robert L. Ferris (University of Pittsburgh)H-Index: 92
view all 24 authors...
Background: Patients (pts) with platinum-refractory R/M SCCHN have an extremely poor prognosis and no chemotherapy (CT) options to extend survival. Nivo, a fully human anti-programmed death-1 monoclonal antibody, is FDA-approved and improves survival in other tumor types. Methods: A randomized, open-label, phase 3 trial (NCT02105636) assigned pts (stratified by prior cetuximab) with SCCHN who progressed within 6 mo of platinum-based CT in a 2:1 ratio to nivo 3 mg/kg Q2W or weekly single-agent IC...
32 CitationsSource
#1Amita PatnaikH-Index: 74
#2Lee S. Rosen (UCLA: University of California, Los Angeles)H-Index: 57
Last. Geoffrey I. Shapiro (Harvard University)H-Index: 103
view all 24 authors...
We evaluated the safety, pharmacokinetic profile, pharmacodynamic effects, and antitumor activity of abemaciclib, an orally bioavailable inhibitor of cyclin-dependent kinases (CDK) 4 and 6, in a multicenter study including phase I dose escalation followed by tumor-specific cohorts for breast cancer, non–small cell lung cancer (NSCLC), glioblastoma, melanoma, and colorectal cancer. A total of 225 patients were enrolled: 33 in dose escalation and 192 in tumor-specific cohorts. Dose-limiting toxici...
362 CitationsSource
#1Irene Guijarro (University of Texas MD Anderson Cancer Center)H-Index: 2
#2Warren Denning (University of Texas MD Anderson Cancer Center)H-Index: 6
Last. John V. Heymach (University of Texas MD Anderson Cancer Center)H-Index: 97
view all 12 authors...
e20099Background: Small cell lung cancer (SCLC) is an aggressive form of lung cancer characterized by loss of the tumor suppressor Rb. Chemotherapy and radiation remain the standard of care for SCL...
1 CitationsSource
Cyclins and cyclin-dependent protein kinases (CDKs) are important regulatory components that are required for cell cycle progression. The levels of the cell cycle CDKs are generally constant and their activities are controlled by cyclins, proteins whose levels oscillate during each cell cycle. Additional CDK family members were subsequently discovered that play significant roles in a wide range of activities including the control of gene transcription, metabolism, and neuronal function. In respo...
115 CitationsSource
#2Delphine Antoni (UDS: University of Strasbourg)H-Index: 13
Last. Georges Noël (UDS: University of Strasbourg)H-Index: 33
view all 9 authors...
Abstract Background To assess relevance of ESMO-ESSO-ESTRO treatment guidelines in a retrospective analysis of patients with anal canal or anal margin cancers. Material and methods 155 patients were separated into standard treatment group (STG), treated according to or closely the guidelines, and an altered treatment group (ATG). Results The median follow-up time was 50.7 months. In the STG, the 5- and 10-year LR-DFS rates were 75.2% and 72.7%; in the ATG, they were 66.8% and 61.2%, respectively...
10 CitationsSource
#1Wensheng Zhang (XULA: Xavier University of Louisiana)H-Index: 11
#2Andrea Edwards (XULA: Xavier University of Louisiana)H-Index: 9
Last. Kun Zhang (XULA: Xavier University of Louisiana)H-Index: 15
view all 5 authors...
Patients with HPV-positive head neck squamous cell carcinomas (HNSCC) usually have a better prognosis than the HPV-negative cases while the underlying mechanism remains far from being well understood. We investigated this issue by an integrative analysis of clinically-annotated multi-omics HNSCC data released by the Cancer Genome Atlas. As confirmatory results, we found: (1) Co-occurrence of mutant TP53 and HPV infection was rare; (2) Regardless of HPV status, HNSCCs of wild-type TP53 implied a ...
12 CitationsSource
#1Roy S. Herbst (Yale University)H-Index: 109
#2Paul Baas (NKI-AVL: Netherlands Cancer Institute)H-Index: 72
Last. Edward B. Garon (UCLA: University of California, Los Angeles)H-Index: 61
view all 19 authors...
Summary Background Despite recent advances in the treatment of advanced non-small-cell lung cancer, there remains a need for effective treatments for progressive disease. We assessed the efficacy of pembrolizumab for patients with previously treated, PD-L1-positive, advanced non-small-cell lung cancer. Methods We did this randomised, open-label, phase 2/3 study at 202 academic medical centres in 24 countries. Patients with previously treated non-small-cell lung cancer with PD-L1 expression on at...
3,609 CitationsSource
#1Charles J. Sherr (St. Jude Children's Research Hospital)H-Index: 117
#2David H. Beach (QMUL: Queen Mary University of London)H-Index: 8
Last. Geoffrey I. Shapiro (Harvard University)H-Index: 103
view all 3 authors...
Biochemical and genetic characterization of D-type cyclins, their cyclin D–dependent kinases (CDK4 and CDK6), and the polypeptide CDK4/6 inhibitor p16INK4 over two decades ago revealed how mammalian cells regulate entry into the DNA synthetic (S) phase of the cell-division cycle in a retinoblastoma protein–dependent manner. These investigations provided proof-of-principle that CDK4/6 inhibitors, particularly when combined with coinhibition of allied mitogen-dependent signal transduction pathways...
481 CitationsSource
#1Erika Hamilton (Sarah Cannon Research Institute)H-Index: 26
#2Jeffrey R. Infante (Sarah Cannon Research Institute)H-Index: 68
Abstract The cyclin D-cyclin dependent kinase (CDK) 4/6-inhibitor of CDK4 (INK4)-retinoblastoma (Rb) pathway controls cell cycle progression by regulating the G1-S checkpoint. Dysregulation of the cyclin D-CDK4/6-INK4-Rb pathway results in increased proliferation, and is frequently observed in many types of cancer. Pathway activation can occur through a variety of mechanisms, including gene amplification or rearrangement, loss of negative regulators, epigenetic alterations, and point mutations i...
209 CitationsSource
#1Hanyu Cao (Sichuan University)H-Index: 1
#2Si Wang (Sichuan University)H-Index: 1
Last. Jiangyan Lou (Sichuan University)H-Index: 1
view all 4 authors...
Objective This study aimed to examine the prognostic value of overexpressed p16INK4a in vulvar cancer. Although the tumor suppressor p16INK4a has been shown to be of prognostic value in a wide variety of cancers and precancerous lesions, its role in the vulvar cancer is still unclear. Methods All publications in English language on the association between p16INK4a and clinicopathological features of vulvar cancer were searched from Pubmed, Embase, and Web of Science, and those in Chinese languag...
16 CitationsSource
Cited By9
Newest
#1Yuan Liu (Huda: Hubei University)H-Index: 1
#2Runsheng Zhao (Huda: Hubei University)H-Index: 1
Last. Bo Liu (Huda: Hubei University)H-Index: 2
view all 6 authors...
: Cervical cancer is the second most common malignancy in women and the novel therapeutic treatment is needed. Abemaciclib is a FDA-approved drug for breast cancer treatment. In this work, we identified that abemaciclib has potent anti-cervical cancer activity. We demonstrate that abemaciclib is the most effective drug against human papillomavirus (HPV)-negative cervical cancer cells compared to ribociclib and palbociclib, with its IC50 at nanomolar concentration range. This is achieved by the i...
4 CitationsSource
#1Franco Guscetti (UZH: University of Zurich)H-Index: 27
#2Sina Nassiri (Swiss Institute of Bioinformatics)H-Index: 11
Last. Enni Markkanen (UZH: University of Zurich)H-Index: 16
view all 6 authors...
Spontaneously occurring canine oral squamous cell carcinomas (COSCC) are viewed as a useful model for human head and neck squamous cell carcinomas (HNSCC). To date however, the molecular basis of COSCC remains poorly understood. To identify changes pertinent to cancer cells in COSCC, we specifically analyzed tumor cells and matched normal epithelium from clinical formalin-fixed paraffin-embedded specimens using laser-capture-microdissection coupled with RNA-sequencing (RNAseq). Our results ident...
4 CitationsSource
#1Eric Remer (Meir Medical Center)H-Index: 1
#2Mai Badarni (BGU: Ben-Gurion University of the Negev)H-Index: 2
Last. Aviram Mizrachi (TAU: Tel Aviv University)H-Index: 14
view all 13 authors...
Activating alterations in PIK3CA, the gene coding for the catalytic subunit of phosphoinositide-3-kinase (PI3K), are prevalent in head and neck squamous cell carcinoma (HNSCC) and thought to be one of the main drivers of these tumors. However, early clinical trials on PI3K inhibitors (PI3Ki) have been disappointing due to the limited durability of the activity of these drugs. To investigate the resistance mechanisms to PI3Ki and attempt to overcome them, we conducted a molecular-based study usin...
3 CitationsSource
#1Wonkyun Ronny ImH-Index: 2
#2Hyun-Sung Lee (BCM: Baylor College of Medicine)H-Index: 25
Last. Yong Sun LeeH-Index: 19
view all 13 authors...
Nc886 is a regulatory non-coding RNA (ncRNA) whose expression is frequently silenced in malignancies. In the case of esophageal squamous cell carcinoma (ESCC), nc886 silencing is associated with shorter survival of patients, suggesting nc886′s tumor suppressor role in ESCC. However, this observation has not been complemented by an in-detail study about nc886′s impact on gene expression and cellular phenotypes. Here we have shown that nc886 inhibits AKT, a key protein in a renowned pro-survival p...
4 CitationsSource
#1Corina LorzH-Index: 29
#2Carmen SegrellesH-Index: 23
Last. Ramón García-EscuderoH-Index: 33
view all 4 authors...
1 CitationsSource
#1Ting Yan (HKUST: Hong Kong University of Science and Technology)H-Index: 6
#2Heyang Cui (HKUST: Hong Kong University of Science and Technology)H-Index: 7
Last. Qimin Zhan (PKU: Peking University)H-Index: 10
view all 33 authors...
Esophageal squamous cell carcinoma (ESCC) ranks fourth among cancer-related deaths in China due to the lack of actionable molecules. We performed whole-exome and T-cell receptor (TCR) repertoire sequencing on multi-regional tumors, normal tissues and blood samples from 39 ESCC patients. The data revealed 12.8% of ERBB4 mutations at patient level and functional study supported its oncogenic role. 18% of patients with early BRCA1/2 variants were associated with high-level contribution of signature...
41 CitationsSource
#1Yuhua GongH-Index: 1
#2Jinzhong MaoH-Index: 1
Last. Rong SongH-Index: 1
view all 7 authors...
Background Accumulating data indicated that circRNA plays important roles in regulating many biological processes of the tumor, the present study is designated for exploring roles of the circ-ZEB1.33-miR-200a-3p-CDK6 regulating axis in human hepatocellular carcinoma (HCC).
54 CitationsSource
#1Se Jin Oh (KU: Korea University)H-Index: 11
#2Hanbyoul Cho (Yonsei University)H-Index: 21
Last. Tae Woo Kim (KU: Korea University)H-Index: 34
view all 17 authors...
Immunoediting caused by antitumor immunity drives tumor cells to acquire refractory phenotypes. We demonstrated previously that tumor antigen–specific T cells edit these cells such that they become resistant to CTL killing and enrich NANOG high cancer stem cell-like cells. In this study, we show that synaptonemal complex protein 3 (SCP3), a member of the Cor1 family, is overexpressed in immunoedited cells and upregulates NANOG by hyperactivating the cyclin D1–CDK4/6 axis. The SCP3–cyclin D1–CDK4...
16 CitationsSource
#1R. Costa (NU: Northwestern University)H-Index: 7
#2R.B. Costa (NU: Northwestern University)H-Index: 1
Last. William J. Gradishar (NU: Northwestern University)H-Index: 68
view all 9 authors...
Abstract Purpose Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors such as palbociclib and ribociclib are associated with distinct adverse effects (AEs) compared to other targeted therapies. This meta-analysis of clinical trials summarizes these agents' toxicity profile. Methods A librarian-guided literature search was conducted in March of 2017. The trials needed to have at least one of the study arms consisting of palbociclib or ribociclib monotherapy at currently FDA approved dose regimens....
8 CitationsSource